US 9,808,479 B2
SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions
Ana Isabel Jimenez Anton, Madrid (ES); Victoria Gonzalez Fajardo, Madrid (ES); and Veronica Ruz Palomar, Madrid (ES)
Assigned to SYLENTIS SAU, Madrid (ES)
Appl. No. 14/425,459
Filed by Sylentis SAU, Madrid (ES)
PCT Filed Sep. 4, 2013, PCT No. PCT/EP2013/068245
§ 371(c)(1), (2) Date Mar. 3, 2015,
PCT Pub. No. WO2014/037377, PCT Pub. Date Mar. 13, 2014.
Claims priority of application No. 1215857.2 (GB), filed on Sep. 5, 2012.
Prior Publication US 2015/0224131 A1, Aug. 13, 2015
Int. Cl. A61K 48/00 (2006.01); C12N 15/11 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/7088 (2006.01); C12N 15/113 (2010.01)
CPC A61K 31/7088 (2013.01) [C12N 15/1138 (2013.01); C12N 2310/14 (2013.01); C12N 2310/321 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating dry eye and/or ocular pain in a subject in need thereof, said method comprising administering topically to the eye of the subject an siRNA having the sequence as set forth in SEQ ID NO: 2 and targeted to SEQ ID NO: 1, said siRNA administered at a dosage of 0.3 mg to 0.9 mg per day; wherein the dosage is effective in reducing dry eye and/or ocular pain in the subject undergoing treatment.